• ქართული
  • English
  • Sarepta surges after Pfizer gene therapy data raises safety concerns

    Shares of Sarepta Therapeutics Inc surged 15% on Friday after some safety concerns were raised in a small, early-stage study of a competing gene therapy for a rare muscle-wasting disorder from Pfizer Inc .

    Market Quotes by TradingView